Drug: Ixifi (infliximab-qbtx)

Manufacturer: Pfizer

Route of Administration: Intravenous

Site of Care: Outpatient

Approved Indication:

• • reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
  • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
  • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
  • [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease
  • reducing signa and symptoms in adult patients with active ankylosing spondylitis
  • reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
  • treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate

Disease: ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

Enrollment Form Link: N/A

Phone Number: N/A

Fax Number: N/A

Product Website: www.pfizer/com/ixifi